Israel Englander Syndax Pharmaceuticals Inc Transaction History

Millennium Management LLC

$199 Billion
Q3 2024

A detailed history of Israel Englander (Millennium Management LLC) transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Millennium Management LLC holds 1,119,963 shares of SNDX stock, worth $14.6 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

1,119,963

Previous 1,065,508 5.11%

Holding current value

$14.6 Million

Previous $21.9 Million 1.44%

% of portfolio

0.01%

Previous 0.01%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$17.93 - $24.81 $976,378 - $1.35 Million	54,455 Added 5.11%	1,119,963 $21.6 Million
Q2 2024 Aug 14, 2024	BUY	$18.82 - $23.79 $7.22 Million - $9.13 Million	383,634 Added 56.26%	1,065,508 $21.9 Million
Q1 2024 May 15, 2024	SELL	$19.71 - $24.57 $5.14 Million - $6.41 Million	-260,768 Reduced 27.66%	681,874 $16.2 Million
Q4 2023 Feb 14, 2024	BUY	$11.39 - $21.67 $9.01 Million - $17.1 Million	790,942 Added 521.39%	942,642 $20.4 Million
Q2 2023 Aug 14, 2023	BUY	$19.35 - $22.31 $2.13 Million - $2.45 Million	109,972 Added 263.54%	151,700 $3.18 Million
Q1 2023 May 15, 2023	BUY	$20.66 - $28.98 $862,100 - $1.21 Million	41,728 New	41,728 $881,000
Q2 2022 Aug 15, 2022	SELL	$13.64 - $19.48 $5.48 Million - $7.82 Million	-401,512 Reduced 94.23%	24,601 $473,000
Q1 2022 May 16, 2022	BUY	$14.84 - $22.15 $6.05 Million - $9.02 Million	407,351 Added 2171.15%	426,113 $7.41 Million
Q4 2021 Feb 14, 2022	SELL	$15.23 - $22.47 $275,495 - $406,459	-18,089 Reduced 49.09%	18,762 $411,000
Q3 2021 Nov 15, 2021	SELL	$13.87 - $19.8 $2.32 Million - $3.31 Million	-166,994 Reduced 81.92%	36,851 $704,000
Q2 2021 Aug 16, 2021	BUY	$13.42 - $25.18 $2.74 Million - $5.13 Million	203,845 New	203,845 $3.5 Million
Q1 2021 May 17, 2021	SELL	$19.28 - $24.59 $14.6 Million - $18.6 Million	-757,147 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$15.1 - $26.44 $787,359 - $1.38 Million	-52,143 Reduced 6.44%	757,147 $16.8 Million
Q3 2020 Nov 16, 2020	SELL	$13.39 - $17.48 $706,429 - $922,209	-52,758 Reduced 6.12%	809,290 $11.9 Million
Q2 2020 Aug 14, 2020	BUY	$8.94 - $20.98 $5.19 Million - $12.2 Million	580,957 Added 206.68%	862,048 $12.8 Million
Q1 2020 May 14, 2020	BUY	$6.65 - $12.03 $1.68 Million - $3.03 Million	252,070 Added 868.58%	281,091 $3.08 Million
Q4 2019 Feb 14, 2020	SELL	$5.43 - $9.22 $9,632 - $16,356	-1,774 Reduced 5.76%	29,021 $255,000
Q3 2019 Nov 14, 2019	SELL	$7.47 - $10.76 $76,806 - $110,634	-10,282 Reduced 25.03%	30,795 $230,000
Q2 2019 Aug 15, 2019	SELL	$4.9 - $9.31 $2.25 Million - $4.27 Million	-458,923 Reduced 91.78%	41,077 $382,000
Q2 2019 Aug 14, 2019	BUY	$4.9 - $9.31 $2.12 Million - $4.03 Million	432,845 Added 644.55%	500,000 $5.06 Million
Q1 2019 May 14, 2019	BUY	$4.26 - $6.86 $71,099 - $114,493	16,690 Added 33.07%	67,155 $353,000
Q4 2018 Feb 14, 2019	SELL	$3.6 - $8.42 $2.01 Million - $4.69 Million	-557,573 Reduced 91.7%	50,465 $225,000
Q3 2018 Nov 14, 2018	BUY	$6.33 - $8.08 $2.91 Million - $3.71 Million	459,103 Added 308.26%	608,038 $4.91 Million
Q2 2018 Aug 14, 2018	SELL	$6.93 - $14.63 $1.33 Million - $2.81 Million	-192,378 Reduced 56.36%	148,935 $1.05 Million
Q1 2018 May 15, 2018	SELL	$8.71 - $14.82 $1.53 Million - $2.6 Million	-175,187 Reduced 33.92%	341,313 $4.86 Million
Q4 2017 Feb 14, 2018	BUY	$7.8 - $12.94 $641,596 - $1.06 Million	82,256 Added 18.94%	516,500 $4.53 Million
Q3 2017 Nov 14, 2017	BUY	$10.9 - $12.73 $4.73 Million - $5.53 Million	434,244	434,244 $5.08 Million

Others Institutions Holding SNDX

# of Institutions

228

Shares Held

88.4M

Call Options Held

1.01M

Put Options Held

692K

View Full List

About Syndax Pharmaceuticals Inc

Ticker SNDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,565,200
Market Cap $740M
Description
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...

More about SNDX

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account